AG
CRL icon

Ascent Group’s Charles River Laboratories CRL Stock Holding History

Ascent Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,935
Closed -$1.49M – 466
2022
Q2 		$1.49M Buy
5,935
+15
+0.3% +$3.67K 0.18% 175
2022
Q1 		$1.68M Buy
5,920
+404
+7% +$125K 0.2% 173
2021
Q4 		$1.79M Buy
+5,516
New +$2.14M 0.23% 162

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Ascent Group's CRL Position: Q3 2022 in Review

Ascent Group sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 5,935 shares — an estimated $1.49M sold.

Ascent Group first reported a position in CRL in Q4 2021 and held it in 3 quarters. The position peaked at $1.79M in Q4 2021. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Ascent Group reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
  • Ascent Group sold 5,935 Charles River Laboratories shares in Q3 2022, an estimated $1.49M.
  • Ascent Group first reported a position in Charles River Laboratories in Q4 2021 and held it in 3 quarters.
  • Ascent Group's Charles River Laboratories position peaked at $1.79M in Q4 2021.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Ascent Group's 13F filing for Q3 2022, filed 15 Nov 2022.